Mylan Pharmaceuticals, Inc.
Generic Division of Mylan Laboratories Inc.
781 Chestnut Ridge Road
Morgantown
West Virginia
26505
United States
Tel: 800-RX-MYLAN
Website: http://www.mylan.com/
61 articles about Mylan Pharmaceuticals, Inc.
-
The U.S. Court of Appeals for the Federal Circuit denied Biogen a second look into the patent dispute filed against Mylan for Biogen's Multiple Sclerosis (MS) drug, Tecfidera.
-
Viatris is First to Receive FDA Approval of Generic Restasis® (Cyclosporine Ophthalmic Emulsion 0.05%) to Treat Dry Eye Disease
2/3/2022
Viatris Inc. (NASDAQ: VTRS) today announced that its subsidiary, Mylan Pharmaceuticals Inc., has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Cyclosporine Ophthalmic Emulsion 0.05%, the first generic version of Allergan's Restasis®.
-
Viatris executive chairman Robert Coury said that seeking new stewards for the site is the best route to ensure that people will have jobs and that the property would remain useful.
-
Anaphylaxis is a serious and potentially fatal allergy to bee venom, food, and medication, and only 50-60% of the affected population is adequately prepared for an attack. Even less are prepared in severe cases where a second dose is required.
-
Mylan Pharmaceuticals Initiates Voluntary Nationwide Recall of One Lot of Alprazolam Tablets, USP C-IV 0.5 mg, Due to the Potential of Foreign Substance
10/25/2019
Mylan Pharmaceuticals Inc. is conducting a voluntary nationwide recall of one lot of Alprazolam Tablets, USP C-IV 0.5 mg, to the consumer/user level.
-
Ironwood and Allergan Announce Settlement with Mylan Resolving LINZESS® (linaclotide) Patent Litigation
1/2/2019
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Mylan Pharmaceuticals, Inc. (NASDAQ: MYL) resolving patent litigations brought in response to Mylan’s abbreviated new drug applications (ANDAs) seeking approval to market generic versions of LINZESS (linaclotide) prior to the expiration of the companies’ applicable patents.
-
Information Update - Mylan-Valsartan medications voluntarily recalled as a precaution due to an impurity
11/29/2018
Mylan Pharmaceuticals ULC is voluntarily recalling four lots of Mylan-Valsartan tablets (40 mg, 80 mg, 160 mg and 320 mg strength) after testing found low levels of an impurity, N-nitrosodiethylamine (NDEA).
-
InSite Vision Announces Settlement Of Patent Infringement Lawsuit Against Mylan Pharmaceuticals, Inc.
3/17/2015
-
Mylan Pharmaceuticals, Inc. Recalls Nitroglycerin Spray Due To Defective Pump
9/22/2014
-
Mylan Inc. Launches Generic Prandin® Tablets
1/24/2014
-
Mylan Inc. Launches Generic Detro® LA Capsules
1/8/2014
-
Mylan Inc. Announces STALEVO® Settlement Agreement
7/25/2013
-
InSite Vision Announces Joint Patent Infringement Lawsuit With Merck & Co., Inc. Against Mylan Pharmaceuticals, Inc.
6/17/2013
-
Mylan Pharmaceuticals, Inc. Gets FDA Approval for New Product
11/29/2012
-
Pfizer Inc. Settles Patent Litigation With Mylan Inc. Covering Detrol LA®
9/7/2012
-
Mylan Pharmaceuticals, Inc. Gets FDA Approval for Generic Diabetes Med
8/20/2012
-
Somaxon Pharmaceuticals, Inc. Announces Settlement of Silenor Patent Litigation With Mylan Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc.
7/18/2012
-
Mylan Pharmaceuticals, Inc. Settles Provigil® Litigation With Teva Pharmaceutical Industries Limited
6/8/2012
-
Mylan Pharmaceuticals, Inc.'s Generic Version of Blood-Thinner Plavix Gets FDA Approval
5/18/2012
-
Merck & Co., Inc. Wins Two Patent Lawsuits Against Mylan Pharmaceuticals, Inc.
4/30/2012